Scarica l'app Stockscreener
15.02
0.74%
0.11
Dopo l'orario di chiusura:
15.00
-0.02
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$14.91
Aprire:
$14.83
Volume 24 ore:
1.21M
Relative Volume:
0.66
Capitalizzazione di mercato:
$1.79B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.8316
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
-2.97%
1M Prestazione:
+4.82%
6M Prestazione:
+8.45%
1 anno Prestazione:
+53.74%
Intervallo 1D:
$14.76
$15.17
Intervallo di 1 settimana:
$14.10
$15.78
Portata 52W:
$7.86
$17.75
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
15.02 | 1.73B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis to Report Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025 - The Manila Times
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Using Too Much Debt? - 富途牛牛
What analysts say about Arcutis Biotherapeutics Inc. stockFree Investment Community - Autocar Professional
Arcutis Biotherapeutics Inc. Stock Analysis and ForecastExponential return rates - jammulinksnews.com
Is Arcutis Biotherapeutics Inc. a good long term investmentFree Capital Growth Strategies - jammulinksnews.com
What drives Arcutis Biotherapeutics Inc. stock priceAccelerated wealth building - jammulinksnews.com
Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth - Investing.com India
(ARQT) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Arcutis Biotherapeutics Completes Promising Psoriasis Treatment Study - TipRanks
Is Arcutis Biotherapeutics (NASDAQ:ARQT) Weighed On By Its Debt Load? - simplywall.st
Arcutis Bio EVP Burnett sells $432k in ARQT stock after option exercise - Investing.com Canada
Arcutis’ ZORYVE Receives AAD Recommendation for Adult Atopic Dermatitis - MSN
FDA News and Decisions: Midyear Updates - Dermatology Times
Arcutis Biotherapeutics Stock Scores RS Rating Upgrade - MSN
(ARQT) Investment Analysis - news.stocktradersdaily.com
Arcutis Biotherapeutics - WBFF
Uncovering Plaque Psoriasis: Exploring New FDA-Approved Topical Treatment - ABC Action News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Morgan Stanley assumes coverage of Arcutis Biotherapeutics stock with Overweight rating - Investing.com Nigeria
Arcutis Awards Generous Stock Compensation Package: 14,000 RSUs for Two New Hires - Stock Titan
Arcutis Biotherapeutics: A Closer Look At The Atopic Dermatitis Direction (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics (ARQT) Gains Strong AAD Recommendation for ZORYVE Cream | ARQT Stock News - GuruFocus
ZORYVE Becomes Only Branded Topical to Earn Strong AAD Recommendation for Atopic Dermatitis - Stock Titan
Arcutis Biotherapeutics: Another Approval Under Their Belt - Seeking Alpha
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
When (ARQT) Moves Investors should Listen - news.stocktradersdaily.com
Analysts Expect Breakeven For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Before Long - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Announces Enrolling the First Child in Phase 2 Trials - MSN
Arcutis Biotherapeutics Approves Key Proposals at Annual Meeting - TipRanks
Arcutis: Out Of The Woods, Ready For Commercialization - Seeking Alpha
10 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
First child enrolled in Arcutis’ Phase II trial of cream for atopic dermatitis - Yahoo Finance
Arcutis at Goldman Sachs Conference: Strategic Growth and Challenges By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):